{{Message}}

De Meern, October 13, 2017

The Supervisory Board of European healthcare player Mediq announces the appointment of Paul Hitchin as the new CFO and member of the Mediq Board of Management with effect from 1 January, 2018.

Paul Hitchin has extensive international experience in financial leadership functions. He is a British national and joined Ford Motor Company in 2001 where he worked in finance. Since 2004, he has held global CFO positions at General Electric, amongst others in the healthcare industry as CFO of GE Biotechnologies and most recently as global CFO of General Electric Mining. He will use his specialized business expertise to further strengthen and grow Mediq’s position as an international service provider in institutional healthcare and homecare.

Rob ter Haar, Chairman of the Supervisory Board, said: “Both the Mediq Supervisory Board and the Management Team are enthusiastic about Paul Hitchin taking up this position. We are convinced that Paul, with his ample experience and proven track record, will help us execute our growth strategy while at the same time continuing Mediq’s track record of successful acquisitions.”

De Meern, June 01, 2017

Mediq has acquired ACC Nordic AS and ACC Nordic AB, distributors of clinical laboratory diagnostics in Norway and Sweden, respectively. The products are an expansion of Mediq’s current laboratory product portfolio in Finland and Estonia to additional Nordic countries, strengthening Mediq’s market position in the Nordics.

ACC Nordic is a company of high product and customer expertise and specialized in sales, marketing and servicing of diagnostics products in Norway and in Sweden. ACC Nordic products are directed to the central laboratory as well as the point of care, and deal with patients of various illnesses and trauma. The acquisition advances Mediq’s strategy offering specialized products to hospitals to ensure our customers can give high level care to their patients. 
 
Jørgen Kelkjær, EVP Nordics and Baltics: “Clinical diagnostics laboratories are an important customers segment for Mediq in Finland and the Baltics. ACC Nordic is a perfect and natural fit for us and we look forward to bringing pan-Nordic benefits with local expertise to both existing and potential future suppliers.”
Both parties have agreed not to disclose the financial details of the transaction.

Paris, May 29, 2017


Through this acquisition, the new group aspires to become a European leader in the medical materials market and aims to strengthen its digital offering as well as its positioning on the general and specialist practitioners segments.

Hervé Liebermann, Novomed Group CEO, said: "There's an obvious complementarity between our Companies that this strategic acquisition provides: complementarity between Novomed's production & sourcing expertise and Mediq's mastery of online distribution on the one hand, and complementarity between our clienteles (hospitals and independent practitioners) on the other. This marriage will help us to build a French medical materials champion capable of accelerating its digital transition and its international development."

Mediq France Management will continue to exist after the merging of the two companies into one Group.

Aurélie Descubes, Mediq France CEO, added, "Mediq France has succeeded in implementing major changes in its organization to address our customers' needs more efficiently. Our joining up with Novomed Group gives us the opportunity to move forward. With more than 100 000 clients in France and in Europe, the group will be unique in the innovation of its products and its service offering. With this in mind, our ability to continue our rapid growth in the digital field will be vital to achieve our strategic goals.

The operation was financed by senior and junior mezzanine debt arranged by Capzanine and through bank syndication including LCL, BNP Paribas and Caisse d'Epargne Ile-de-France, cofinanced by BPIfrance. The financial due-diligence was carried out by Aca Nexia, while PGA acted as legal advisors and D&A as financial advisors for Novomed Group's shareholders. Mediq Group was advised by Jones Day.

About Novomed
Established in 1993, Novomed Group is specialized in the conception, manufacturing and distribution of disposable medical kits that have become key tools in the fight against healthcare-associated or hospital-acquired infections.

France's leader in the gynecological-obstetrical and aesthetical-dermatological segments through its business units "Laboratoire Gyneas" and "Laboderm", the Group has been driven by a strong innovative and entrepreneurial spirit since its foundation. Novomed has developed other business units such as the cosmetics brand Moraz, the cosmetotextile lines Beautyline and Arnitex and the range of comfort products for senior citizens Novo'Life.

Press release of Novomed Group. 

De Meern, May 09, 2017

Breakthrough collaboration by Emma Children's Hospital AMC, KinderThuisZorg and Mediq Children treated for cancer at Emma Children's Hospital AMC in Amsterdam have, in the context of a pilot, been given the opportunity to receive chemotherapy at home. For this purpose, specialist pediatric oncology nurses employed by KinderThuisZorg visited the children at home to determine whether their physical condition allowed the administration of chemotherapy. Mediq ensured safe delivery of the chemotherapy administration system and the medication that is prepared by Emma Children’s Hospital AMC. "Children and their parents need to go to the hospital less often for chemotherapy. This makes the treatment less stressful," says Dr. Marianne van de Wetering, pediatric oncologist and chef de clinique pediatric oncology at Emma Children's Hospital AMC, who supervised this pilot with specialist pediatric oncology nurse Charlotte Beukhof.

Less stressful
Children with leukemia could already receive a small part of their chemotherapy at home. This is now also possible for other types of chemotherapy that can only be administered after interpreting blood test results, a physical examination and a consultation. A unique development in the care of sick children outside the hospital. "The children can simply stay in their own living environment and spend less time in the hospital. This increases the quality of life and reduces social impact. At the same time, this cooperation strengthens the bridge between hospital care and home care,” van de Wetering says.

Treatments by specialist pediatric oncology nurses
KinderThuisZorg is the first pediatric home health care service agency in the Netherlands to employ specialized oncology nurses. “These specialist pediatric nurses provide the oncology treatments at home. In the past, the children had to visit the hospital weekly or sometimes more often to have chemotherapy as part of their treatment,” says Natascha Kok, pediatric oncology nurse and comfort care specialist at KinderThuisZorg.

Safe care in familiar surroundings
"Good organization and cooperation are the keys to care transitions from hospital to home,” emphasizes Xander Schrage, director of Mediq Tefa. “To enable a safe and seamless transfer we have developed an integral approach with KinderThuisZorg and Emma Children's Hospital AMC. This creates new opportunities to provide the best possible care in a familiar environment.”

A normal day at school
To ensure quality, Emma Children's Hospital AMC, KinderThuisZorg and Mediq have conducted a pilot project during three months. Roemer and Justin (both age eight) participated in the pilot, and can be followed on www.deproeftest.nl. “I hope this test can continue, that would be great,” says Roemer. “When I receive chemotherapy at home, I can still go to school all day,” Justin remarks. During the pilot, it was examined whether the desired effect was achieved. To this end, parents have regularly filled out questionnaires on the quality of life and the social impact. Given the positive pilot results, the obvious next step is to continue this approach. Health insurance companies are therefore invited to support administration of chemotherapy in the home environment. This way, this care solution can also be introduced at other children's hospitals.

Press release of KinderThuisZorg, Emma Kinderziekenhuis AMC and Mediq.

RICHMOND, VIRGINIA, May 03, 2017

Owens & Minor (NYSE: OMI) announced today that it has signed a definitive purchase agreement to acquire Byram Healthcare (Byram), a wholly owned subsidiary of Mediq B.V., for approximately $380 million in cash. Headquartered in White Plains, New York, Byram is a leading domestic distributor of medical supplies sold directly to patients and home health agencies. The acquisition is expected to contribute approximately $450 million in incremental annual revenue for Owens & Minor. The company expects that the transaction will have limited impact on 2017 earnings and will be modestly accretive in 2018.

"Expanding across the continuum of care is a strategic imperative for us," said P. Cody Phipps, president & chief executive officer of Owens & Minor. "With the addition of Byram to the Owens & Minor family, we can quickly advance our strategic agenda with providers and manufacturers by expanding our reach beyond the hospital setting all the way to the patient's home. Byram's expertise in managing third party reimbursement and working with insurers and federal health care programs brings an important new capability to Owens & Minor."

In operation since 1968, Byram is a market-leading distributor of reimbursable medical supplies to home patients and home health agencies in the United States. Byram has strong positions in its principal product lines of ostomy, wound care, urology, diabetes, and incontinence supplies, which are sold nationwide. Byram has built a portfolio of over 600 payor contracts covering more than 200 million lives, along with a dedicated revenue cycle management infrastructure to support claims filing and collection processes. With more than 900 teammates, Byram has national reach in the direct-to-patient market in the U.S., which it serves with an experienced management team and a sizable customer-facing sales and service team.
The transaction is expected to close in the third quarter of 2017, subject to various closing conditions and regulatory approvals, including Hart Scott Rodino clearance.

Safe Harbor Statement
This release is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the Securities and Exchange Commission's Fair Disclosure Regulation. This release contains certain ''forward-looking'' statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the timing or our ability to complete the transaction with Byram described herein; the expected benefits and costs of the transaction; any projections of earnings, revenues or other financial items related to the transaction or Byram following closing of the transaction; any statements of the plans, strategies and objectives of management for future operations; any statements regarding product or service development, extensions or integration; any statements regarding Owens & Minor's implementation, operation of growth of the Byram business following closing of the transaction and any statements of assumptions underlying any of the foregoing. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements. Investors should refer to our annual report on Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission ("SEC") and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with or furnished to the SEC, for a discussion of certain known risk factors that could cause our actual results to differ materially from our current estimates. These filings are available at www.owens-minor.com. Additional risks and uncertainties that could impact forward-looking statements made in this release include the inability to complete the transaction with Byram for any reason, including the failure to receive any required regulatory approvals or satisfy any other closing conditions; the inability to integrate the Byram operations within Owens & Minor and to realize any of the expected synergies from the transaction with Byram on a timely basis and without incurring costs beyond those currently expected; the challenges of integrating and retaining key Byram employees; and the effect of any business disruptions during or following the transaction, including as a result of the diversion of management time and attention. Given these risks and uncertainties, we can give no assurances that any forward-looking statements will, in fact, transpire and, therefore, caution investors not to place undue reliance on them. We specifically disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
Owens & Minor uses its Web site, www.owens-minor.com, as a channel of distribution for material company information, including news releases, investor presentations and financial information. This information is routinely posted and accessible under the Investor Relations section.

About Owens & Minor
Owens & Minor, Inc. (NYSE: OMI) is a global healthcare services company dedicated to Connecting the World of Medical Products to the Point of CareSM by providing vital supply chain services to healthcare providers and manufacturers of healthcare products. Owens & Minor provides logistics services across the spectrum of medical products from disposable medical supplies to devices and implants. With logistics platforms strategically located in the United States and Europe, Owens & Minor serves markets where three quarters of global healthcare spending occurs. Owens & Minor's customers span the healthcare market from independent hospitals to large integrated healthcare networks, as well as group purchasing organizations, healthcare products manufacturers, and the federal government. A FORTUNE 500 company, Owens & Minor is headquartered in Richmond, Virginia, and has annualized revenues exceeding $9 billion. For more information about Owens & Minor, visit www.owens-minor.com, follow @Owens_Minor on Twitter, and connect on LinkedIn at www.linkedin.com/company/owens-&-minor

De Meern, April 10, 2017

Improved diabetes (self-)care thanks to collaboration with Slingeland Hospital and ONVZ. Slingeland Hospital in Doetinchem is improving its diabetes care with Mediq DiaCare. This care program comprises a secure e-health platform, an app and education. A diabetes patient and their diabetes specialist nurse can opt for a blood glucose meter that can send the measured blood sugar level to the app that provides continuous feedback. This insight allows for improved self-management and confident health decisions. This secure digital environment also keeps the diabetes nurse involved in the care process. The program has been extensively tested at Slingeland Hospital and is supported by ONVZ Healthcare Insurer.

“We see that our patients check their blood sugar levels more actively, and grow in their independence,” says Jolanda Geessink, diabetes nurse at Slingeland Hospital. “The DiaCare app instantly shows them the effect of a given behavior or food on their blood sugar level. Patients tell us that this makes them better at preventing excessively high or low blood sugar levels, because they can see what causes them. Diabetes nursing staff can adopt a more proactive and coaching role – which is more agreeable for them as well as for patients.”

A smarter, more effective care process
“We’re also in discussion with other hospitals about using Mediq DiaCare. This solution encourages a patient-centered approach and makes diabetes care more efficient and effective. A single platform gives diabetes patients and their doctors alike up-to-the-minute information on blood glucose levels, education and consultation preparation. This gives a better overview of diabetes regulation and promotes self-management. Delivering this kind of customized care not only yields better health outcomes, it also helps controlling healthcare expenditures,” explains Marco Verhofstadt, Director of Mediq Direct Diabetes.

More patient-friendly care
ONVZ Zorgverzekeraar is the first healthcare insurer to support Mediq DiaCare. “It is a good example of how technology can improve health care and, in particular, make it more patient-friendly,” says CEO Jean-Paul van Haarlem. “Diabetes has a huge impact on a person’s life. Eating habits have to be adapted, insulin must be regularly injected, and don’t forget the hospital visits. Improved insight into blood sugar levels provides people with diabetes with more effective self-management, and that leads to a better balance as well as better health.”

Measuring the health outcomes and care cost effects
Slingeland Hospital and Mediq are currently measuring the effects of this care program on health outcomes and care costs in order to assess its added value. The hospital test group has been expanded; 120 patients use the app and the glucose meter, and are being coached by diabetes nursing staff using the DiaCare e-health portal. Mediq DiaCare will be further optimized and developed on the basis of the findings. Effect measurements are being supervised by the IQ healthcare research department of Radboudumc. The results of this research are expected to appear in late 2017.

About diabetes
Every year another 61,700 people in the Netherlands are told they have diabetes and have to adapt their lives accordingly. This means paying constant attention to what you eat and do, and doing whatever is necessary to keep your blood sugar levels within given boundaries. Further information is available at www.mediqdirectdiabetes.nl/diacare.

About Mediq DiaCare
Mediq DiaCare is a care program which helps people with diabetes to, together with their diabetes care professionals, improve self-management and to deploy consultations, education and contact hours remotely and more effectively. The aims of the program are to deliver a smarter and more efficient care process, lower care costs, and provide better health outcomes. The care program was designed for all people with diabetes. It’s implementation starts at hospitals seeking to optimize their diabetes therapy.

De Meern, March 21, 2017


Mediq, supplier of medical devices and healthcare solutions, has started building a technologically advanced distribution center in Bleiswijk. This 20,000 square meter facility will house the entire Mediq assortment of over 20,000 products. Upon completion and testing, the Mediq distribution centers in Didam, Moordrecht, Nieuwegein and Oud-Beijerland will gradually move to the new location in the first quarter of 2018.

“With this balanced concept all Mediq business models gain speed, logistics service quality and cost efficiency. Not only for our at-home healthcare solutions but also for provision of medical devices and healthcare solutions to hospitals, health care facilities and primary care practices. This innovation also supports our ambition to grow in volume and assortment,” says Mediq Director Vincent Weijers.

Central location
Mediq has chosen this new location in the Prisma Business Park because of its central location and easy access. The new distribution center is being realized by WDP and VDR Construction Group and automated by warehouse logistics specialist Knapp. It will meet the BREEAM sustainability requirements as well as the highest quality standards for safe and secure handling of medical devices and pharmaceuticals.

Ergonomic work environment
For the warehouse staff, limited manual order picking and ergonomic workstations lead to better conditions. 1,500 square meters of the warehouse space will house offices and special areas for activities such as tailor-made ostomy solutions and cleaning and decontamination of medical pumps. The floor space is increased with a 4,000 square meter mezzanine floor for service activities such as medical equipment maintenance and calibration, and repackaging of articles according to customer needs.

De Meern, March 16, 2017

The Supervisory Board hereby announces that Arthur de Bok resigned as CEO and will leave the company to pursue other career interests. Rob ter Haar, chairman of the Supervisory Board said: “Arthur has successfully led Mediq in a new strategic direction with a focus on growing the international Direct to Patient and Institutional businesses. To support this, the company has been transformed to bring much greater cooperation between the operating units, with better systems and processes. In parallel, Arthur oversaw the successful divestment of the Pharmacy business in the Netherlands. We wish him every success in his further career.”

Arthur de Bok: “Over the last three years, we have made tremendous progress in turning Mediq into a company that can provide better care at lower cost with better outcomes for chronic patients. I am proud of what we have accomplished and I am confident that the company’s future is bright.”

As the new CEO of Mediq, the Supervisory Board has appointed Christian Wojczewski who as general manager has successfully built the healthcare unit of the Linde Group into a € 3 billion turnover global business. Rob ter Haar: “The Supervisory Board is delighted that Christian has agreed to join Mediq as its CEO. He is a skilled executive with a proven track record in business transformation and brings a wealth of knowledge of healthcare distribution and homecare. Over the past years Mediq invested significantly in people and systems to build a platform for growth. We look forward to working with Christian in capitalizing on our organic growth potential whilst continuing our track record of successful acquisitions.”

Christian Wojczewski: “Mediq has successfully managed the transition into a leading player in institutional healthcare and homecare over the past years. I look forward continuing on the strategic path together with the management team and all Mediq employees.”

The transition of the leadership at Mediq will take place in April.

Mediq.com is using cookies

We use cookies to make Mediq websites easier to use, to deliver a personalised experience on our websites, and to better tailor our products, services and websites to your interests and needs.